• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Inogen Inc

    5/20/25 4:27:39 PM ET
    $INGN
    Industrial Specialties
    Health Care
    Get the next $INGN alert in real time by email
    S-8 1 ingn-2025-05-20-s-8.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on May 20, 2025

    Registration Statement No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    Under

    THE SECURITIES ACT OF 1933

    Inogen, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware

    33-0989359

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

    859 Ward Drive

    Goleta, California 93111

    (Address of principal executive offices)

    Inogen, Inc. Amended and Restated 2023 Equity Incentive Plan

    (Full title of the plan)

    Kevin R.M. Smith

    Chief Executive Officer and President

    Inogen, Inc.

    859 Ward Drive

    Goleta, California 93111

    (Name and address of agent for service)

    (805) 562-0500

    (Telephone number, including area code, of agent for service)

    Copies to:


    Sarah C. Griffiths
    Covington & Burling LLP
    One International Place, Suite 1020
    Boston, MA 02110
    Telephone: (617) 603-8800

    Kevin P. Smith
    General Counsel
    Inogen, Inc.
    859 Ward Drive
    Goleta, California 93111
    Telephone: (805) 562-0500

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    ☐

    Accelerated filer

    ☒

    Non-accelerated filer

    ☐

    Smaller reporting company

    ☒

     

     

     Emerging growth company

    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     


     

    EXPLANATORY NOTE

    This Registration Statement on Form S-8 (the “Registration Statement”) of Inogen, Inc. (the “Company” or the “Registrant”) registers an additional 750,000 shares of common stock of the Registrant, par value $0.001 per share (“Common Stock”), reserved for issuance pursuant to future awards under the Registrant’s Amended and Restated 2023 Equity Incentive Plan (the “2023 Plan”). This share increase was approved by the Company’s stockholders at an annual meeting of stockholders held on May 14, 2025. In accordance with Section E of the General Instructions to Form S-8, the contents of the previous registration statements on Form S-8 filed by the Registrant with the Securities and Exchange Commission (the “Commission”) on June 7, 2023 (File No. 333-272468) and June 12, 2024 (File No. 333-280151) are incorporated by reference herein, except to the extent supplemented, superseded or modified by the specific information set forth below or the specific exhibits attached hereto. In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of Form S-8 has been omitted from this Registration Statement.

    PART II

    INFORMATION REQUIRED IN REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The Registrant is subject to the informational and reporting requirements of Sections 13(a), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and in accordance therewith files reports, proxy statements and other information with the Commission. The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed with the Commission:

    (1)
    The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on February 28, 2025.
    (2)
    The Registrant’s Quarterly Report on Form 10-Q for the period ended March 31, 2025, filed with the Commission on May 8, 2025.
    (3)
    The Registrant's Current Reports on Form 8-K filed on January 27, 2025, February 3, 2025 and May 19, 2025 (other than information furnished rather than filed in any such report).
    (4)
    All other reports filed with the Commission pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrant’s Annual Report referred to in (1) above (other than information furnished rather than filed in any such report).
    (5)
    The description of the Registrant’s common stock contained in the Company’s Registration Statement on Form 8-A (File No. 001-36309) filed with the Commission on February 10, 2014, pursuant to Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description.

    All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

     


     

    Item 8. Exhibits.

     

     

     

    Incorporated by Reference

    Exhibit
    Number

    Description

    Form

    File No.

    Exhibit

    Filing Date

      4.1

    Specimen common stock certificate of Registrant.

    S-1/A

    333-192605

    4.1

    1/16/14

      4.2+

    Amended and Restated 2023 Equity Incentive Plan.

    8-K

    001-36309

    10.1

    5/19/25

      4.3+

    Form of Stock Option Agreement under the Amended and Restated 2023 Equity Incentive Plan.

    8-K

     

    001-36309

    10.2

    5/19/25

     

      4.4+

    Form of Restricted Stock Unit Agreement - Time-Based under the Amended and Restated 2023 Equity Incentive Plan.

    8-K

     

    001-36309

    10.3

    5/19/25

     

      4.5+

    Form of Restricted Stock Unit Agreement - Performance-Based under the Amended and Restated 2023 Equity Incentive Plan.

    8-K

     

    001-36309

    10.4

    5/19/25

     

      5.1*

    Opinion of Covington & Burling LLP.

     

     

     

     

    23.1*

    Consent of Deloitte and Touche LLP, Independent Registered Public Accounting Firm.

     

     

     

     

    23.2*

    Consent of Covington & Burling LLP (contained in Exhibit 5.1 hereto).

     

     

     

     

    24.1*

    Power of Attorney (contained on signature page hereto).

     

     

     

     

    107*

    Filing Fee Table.

     

     

     

     

    + Indicates management contract or compensatory plan, contract or arrangement.

    * Filed herewith.

     

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Goleta, State of California, on May 20, 2025.

     

    INOGEN, INC.

     

     

    By:

    /s/ Kevin R.M. Smith

     

    Kevin R.M. Smith

     

    Chief Executive Officer, President and Director

    (Principal Executive Officer)

     

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Kevin R.M. Smith and Michael Bourque, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities (including his or her capacity as a director and/or officer of Inogen, Inc.) to sign the Registration Statement on Form S-8 of Inogen, Inc., and any and all amendments (including post-effective amendments) thereto, and to file the same, with all exhibits thereto and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as they, he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

     

    Title

     

    Date

    /s/ Kevin R.M. Smith

     

    Chief Executive Officer, President and Director (Principal Executive Officer)

     

    May 20, 2025

    Kevin R.M. Smith

     

     

    /s/ Michael Bourque

     

    Chief Financial Officer (Principal Accounting and Financial Officer)

     

    May 20, 2025

    Michael Bourque

     

     

    /s/ Elizabeth Mora

     

    Chairperson of the Board

     

    May 20, 2025

    Elizabeth Mora

     

     

    /s/ Glenn Boehnlein

     

    Director

     

    May 20, 2025

    Glenn Boehnlein

     

     

     

     

    /s/ Kevin King

     

    Director

     

    May 20, 2025

    Kevin King

     

     

     

     

    /s/ Mary Katherine Ladone

     

    Director

     

    May 20, 2025

    Mary Katherine Ladone

     

     

     

     

    /s/ Heather Rider

     

    Director

     

    May 20, 2025

    Heather Rider

     

     

     

     

    /s/ Mira Sahney

     

    Director

     

    May 20, 2025

    Mira Sahney

     

     

     

     

     

     


    Get the next $INGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INGN

    DatePrice TargetRatingAnalyst
    6/16/2025$14.00Buy
    B. Riley Securities
    5/22/2025$12.00Hold → Buy
    Needham
    2/15/2024Mkt Perform → Outperform
    William Blair
    8/8/2023$15.00 → $8.00Overweight → Neutral
    JP Morgan
    7/14/2023Buy → Hold
    Needham
    1/17/2023Outperform → Mkt Perform
    William Blair
    12/9/2021$47.00Hold → Buy
    Needham
    11/8/2021$70.00 → $40.00Hold
    Stifel
    More analyst ratings